PAYVANDI, FLORA
PAYVANDI, FLORA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
2024 G. Castaman, F. Peyvandi, J.A. Kremer Hovinga, R.E.G. Schutgens, S. Robson, K. Moreno, V. Jiménez-Yuste
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
2024 G. Di Minno, W. Miesbach, G. Castaman, F. Peyvandi
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
2024 R. Lemons, M. Wang, J. Curtin, L.M. Lepatan, C. Male, F. Peyvandi, M. von Depka Prondzinski, R. Wang, W. Mckeand, W. Seifert, J. Oldenburg
A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results
2024 C. Hermans, L.A. Valentino, C.D. Thornburg, C. Unzu, M.A. Kay, F. Peyvandi, P. Smith, W. Miesbach, W. Mckeown, G.F. Pierce, K. Khair, S.W. Pipe, K. Starcevic, M. Pillai, M. Jones, M. Chiao, I. Antonino, C. Kessler
Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects
2024 A. Lecchi, S. La Marca, L. Padovan, M. Boscarino, F. Peyvandi, A. Tripodi
How the Hemostasis Laboratory can Help Clinicians to Manage Patients on Oral Anticoagulants
2024 A. Tripodi, M. Clerici, E. Scalambrino, P. Agosti, P. Bucciarelli, F. Peyvandi
Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
2024 L. De Waele, K. Sakai, I. Mancini, G. Sinkovits, T. Falter, T. Inoue, P. Agosti, H. Rossmann, C. Von Auer, C. Tersteeg, S.F. De Meyer, B.S. Joly, A. Veyradier, P. Coppo, R. Fijnheer, F. Peyvandi, Z. Prohászka, B. Lämmle, K. Vanhoorelbeke
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database
2024 S. Mohsenian, R. Palla, M. Menegatti, A. Cairo, A. Lecchi, A. Casini, M. Neerman-Arbez, R. Asselta, S. Scardo, S.M. Siboni, J. Blatny, O. Zapletal, J. Schved, M. Giansily-Blaizot, S. Halimeh, M.A. Daoud, H. Platokouki, H. Pergantou, R.E.G. Schutgens, M. Van Haaften-Spoor, P. Brons, B. Laros-van Gorkom, E. Van Pinxten, M. Borhany, N. Fatima, D. Mikovic, M. Saracevic, G.N. Özdemir, Y. Ay, M. Makris, C. Lockley, A. Mumford, A. Harvey, S. Austin, A. Shapiro, A. Williamson, C. Mcguinn, I. Goldberg, P. De Moerloose, F. Peyvandi
Administration of gene therapy for haemophilia – The hub and spoke model and its regional differences and challenges
2024 W. Miesbach, A. Boban, P. Chowdary, M. Coppens, M. Crato, V. Jimenez‐yuste, R. Klamroth, M. Makris, G. Mulders, F. Peyvandi
Landmark endorsement of a global registry: The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), publicly endorses World Federation of Hemophilia Gene Therapy Registry as global standard
2024 B.A. Konkle, F. Peyvandi, D. Coffin, M. Naccache, T. Youttananukorn, G.F. Pierce
Variant p.Tyr1584Cys: a frequent von Willebrand factor variant in search of von Willebrand disease
2024 O. Seidizadeh, L. Baronciani, P. Colpani, G. Cozzi, A. Ciavarella, S.M. Siboni, F. Peyvandi
Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19
2024 R. Rossio, M. Tettamanti, A.A. Galbussera, R. Gualtierotti, A. Giachi, A. Torri, N. Montano, A.L. Fracanzani, A. Bandera, A. Nobili, F. Peyvandi
Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis
2024 S. Arcudi, R. Gualtierotti, E. Scalambrino, M. Clerici, S. Hassan, V. Begnozzi, E.A. Boccalandro, C. Novembrino, C. Valsecchi, R. Palla, F. Peyvandi
Evaluation of an automated platelet aggregation method for detection of congenital or acquired platelet function defects
2024 A. Lecchi, M. Capecchi, L. Padovan, A. Artoni, N. Arai, S. Shinohara, S. La Marca, F. Peyvandi
Insights on the Development of PRACTICE, A Research-Oriented Healthcare Platform
2024 D. Ahmetovic, A. Angileri, S. Arcudi, C. Bettini, G. Civitarese, M. Colussi, A. Giachi, R. Gualtierotti, S. Mascetti, M. Manzoni, F. Peyvandi, A. Solyman, A. Truma
Gender equity in hemophilia: need for healthcare, familial, and societal advocacy
2024 R. Gualtierotti, I. Garagiola, M. Mortarino, S. Spena, O. Romero-Lux, F. Peyvandi
IgM autoantibodies to complement factor H in C3 glomerulopathy
2024 M. Cugno, M.C. Mancuso, F. Depetri, F. Peyvandi, G. Ardissino
Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
2024 S. Agarwal, C. Hermans, W. Miesbach, F. Peyvandi, R. Sidonio, D. Osmond, V. Newman, J. Henshaw, S. Pipe
Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A
2024 O. Seidizadeh, L. Mollica, S. Zambarbieri, L. Baronciani, A. Cairo, P. Colpani, G. Cozzi, M.T. Pagliari, A. Ciavarella, S.M. Siboni, F. Peyvandi
Rare inherited coagulation disorders: no longer orphan and neglected
2024 S. Mohsenian, P.M. Mannucci, M. Menegatti, F. Peyvandi